SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?
ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic is significantly causing unprecedented clinical, socioeconomic, and public health challenges globally. The successful global administration of effective, safe and sustainable vaccine(s) is widely believed to be crucial in mitigating as well a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade de São Paulo
2021-10-01
|
| Series: | Revista de Saúde Pública |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100601&tlng=en |
| _version_ | 1818744610432745472 |
|---|---|
| author | Rine Christopher Reuben Lillian Yami Adogo |
| author_facet | Rine Christopher Reuben Lillian Yami Adogo |
| author_sort | Rine Christopher Reuben |
| collection | DOAJ |
| description | ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic is significantly causing unprecedented clinical, socioeconomic, and public health challenges globally. The successful global administration of effective, safe and sustainable vaccine(s) is widely believed to be crucial in mitigating as well as preventing COVID-19. However, the rising cases of severe adverse events following immunization (AEFI) with COVID-19 vaccines including thrombosis, thrombocytopenia, and in some instances, death have created serious global concerns and could enormously contribute to vaccine hesitancy. Although the complete underlying pathophysiology and immunopathology of the COVID-19 vaccines related to AEFI, including thrombosis and/or anaphylaxis, are yet to be determined, exploring possible immuno-hypersensitivity could be crucial in the mechanisms associated with these reactions, thereby mitigating their occurrences as well as restoring confidence in vaccine administration for a COVID-19 free world. |
| first_indexed | 2024-12-18T02:47:03Z |
| format | Article |
| id | doaj.art-1c0bfe8ef7474a43ba03a3609bf8f6b8 |
| institution | Directory Open Access Journal |
| issn | 1518-8787 |
| language | English |
| last_indexed | 2024-12-18T02:47:03Z |
| publishDate | 2021-10-01 |
| publisher | Universidade de São Paulo |
| record_format | Article |
| series | Revista de Saúde Pública |
| spelling | doaj.art-1c0bfe8ef7474a43ba03a3609bf8f6b82022-12-21T21:23:32ZengUniversidade de São PauloRevista de Saúde Pública1518-87872021-10-015510.11606/s1518-8787.2021055003855SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?Rine Christopher Reubenhttps://orcid.org/0000-0001-8084-2387Lillian Yami Adogohttps://orcid.org/0000-0002-2533-6155ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic is significantly causing unprecedented clinical, socioeconomic, and public health challenges globally. The successful global administration of effective, safe and sustainable vaccine(s) is widely believed to be crucial in mitigating as well as preventing COVID-19. However, the rising cases of severe adverse events following immunization (AEFI) with COVID-19 vaccines including thrombosis, thrombocytopenia, and in some instances, death have created serious global concerns and could enormously contribute to vaccine hesitancy. Although the complete underlying pathophysiology and immunopathology of the COVID-19 vaccines related to AEFI, including thrombosis and/or anaphylaxis, are yet to be determined, exploring possible immuno-hypersensitivity could be crucial in the mechanisms associated with these reactions, thereby mitigating their occurrences as well as restoring confidence in vaccine administration for a COVID-19 free world.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100601&tlng=enCOVID-19, prevention & controlSARS-CoV-2, immunologyCOVID-19 VaccinesImmunogenicity, VaccineEmbolism and Thrombosis |
| spellingShingle | Rine Christopher Reuben Lillian Yami Adogo SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity? Revista de Saúde Pública COVID-19, prevention & control SARS-CoV-2, immunology COVID-19 Vaccines Immunogenicity, Vaccine Embolism and Thrombosis |
| title | SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity? |
| title_full | SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity? |
| title_fullStr | SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity? |
| title_full_unstemmed | SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity? |
| title_short | SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity? |
| title_sort | sars cov 2 vaccines induced thrombotic thrombocytopenia should we consider immuno hypersensitivity |
| topic | COVID-19, prevention & control SARS-CoV-2, immunology COVID-19 Vaccines Immunogenicity, Vaccine Embolism and Thrombosis |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100601&tlng=en |
| work_keys_str_mv | AT rinechristopherreuben sarscov2vaccinesinducedthromboticthrombocytopeniashouldweconsiderimmunohypersensitivity AT lillianyamiadogo sarscov2vaccinesinducedthromboticthrombocytopeniashouldweconsiderimmunohypersensitivity |